Efficacy and Safety of Oxymorphone Extended Release in Opioid-Experienced Patients With Chronic Non-Malignant Pain
NCT ID: NCT00226421
Last Updated: 2024-01-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
120 participants
INTERVENTIONAL
2004-10-31
2005-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Efficacy and Safety of Oxmorphone Extended Release in Chronic Non-malignant Pain
NCT00225797
Oxymorphone Extended Release in Patients With Cancer or Neuropathic Pain
NCT00911261
Open-Label Extension to Evaluate the Long-Term Safety, Tolerability and Analgesic Efficacy
NCT00904280
Oxymorphone Extended Release (ER) in Opioid-Naive Patients With Chronic Pain
NCT00911287
Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain
NCT00214942
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Oxymorphone Extended Release
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* In good health as determined by the Investigator on the basis of medical history and physical examination.
* Moderate to severe chronic non-neuropathic low back pain that has been present daily for at least several hours per day for a minimum of three months prior to the screening.
* On a stable around-the-clock opioid pain medication for the management of moderate to severe chronic lower back pain.
* Expected to require a total daily oxymorphone ER dose that is a minimum of 20 mg per day (oral morphine equivalent: approximately 60 mg) and will not exceed 220 mg oxymorphone ER (oral morphine requirement: approximately 660 mg).
* Any adjunct therapy for back pain such as physical therapy, biofeedback therapy, acupuncture therapy or herbal remedies, based on the patient's current status should remain unchanged during the period of participation of the patient.
* Written informed consent
Exclusion Criteria
* Subjects with radiculopathy, fibromyalgia, reflex sympathetic dystrophy or causalgia (complex regional pain syndrome), acute spinal cord compression, cauda equina compression, acute nerve root compression, severe lower extremity weakness or numbness, bowel or bladder dysfunction secondary to cauda equina compression, diabetic amyotrophy, meningitis, discitis, or back pain due to secondary infection or tumor.
* Cannot or will not agree to stop local regional pain treatments during the study (nerve/plexus blocks or ablation, neurosurgical procedures for pain control, Botulinum toxin injections, or inhalation analgesia). The patient must not have a nerve/plexus block within 4 weeks of screening (Visit 1). The patient must not have a Botulinum toxin injection in the lower back region within 3 months of screening.
* Intend to alter their physical therapy regimen during the study.
* Surgical procedures directed towards the source of back pain within 6 months of screening.
* Pain which is secondary to confirmed or suspected neoplasm.
* Dysphagia or difficulty swallowing tablets or capsules.
* Significant prior history of substance abuse or alcohol abuse.
* Use of any investigational medication within 30 days prior to the first dose of study medication.
* Previous exposure to oxymorphone.
* History of clinically significant intolerance to oxymorphone or a known hypersensitivity to opioid analgesics.
* History of seizure.
* use of MAO inhibitor within 14 days prior to the start of study medication.
* Other clinically significant conditions as judged by the investigator.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Endo Pharmaceuticals
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Southern Drug Research
Hueytown, Alabama, United States
Phoenix Center for Clinical Research
Phoenix, Arizona, United States
Arizona Research
Phoenix, Arizona, United States
Express Care Clinical Research
Colorado Springs, Colorado, United States
Glasgow Family Practice
Newark, Delaware, United States
Radiant Research
Daytona Beach, Florida, United States
University Clinical Research
DeLand, Florida, United States
LCFP Inc.
Fort Myers, Florida, United States
Century Clinical Research
Holly Hill, Florida, United States
Ocala Rheumatology Research Center
Ocala, Florida, United States
The Arthritis Center
Palm Harbor, Florida, United States
Radiant Research
Pinellas Park, Florida, United States
Park Place Therapeutic Center
Plantation, Florida, United States
Comprehensive Neurology Specialists
Atlanta, Georgia, United States
Comprehensive Neuroscience
Atlanta, Georgia, United States
Pain Specialists of Greater Chicago
Burr Ridge, Illinois, United States
Mid-America Physiatrists
Overland Park, Kansas, United States
Research Medical Center
Kansas City, Missouri, United States
Radiant Research
St Louis, Missouri, United States
Comprehensive Clinical Research
Berlin, New Jersey, United States
Piedmont Anesthesia
Winston-Salem, North Carolina, United States
Health Research Institute
Oklahoma City, Oklahoma, United States
Pain Consultants of Oregon
Eugene, Oregon, United States
Keystone Medical Research
Altoona, Pennsylvania, United States
Perkiomen Valley Family Practice
Collegeville, Pennsylvania, United States
Feasterville Family Health Center
Feasterville, Pennsylvania, United States
Fleetwood Clinical Research
Fleetwood, Pennsylvania, United States
Paragon Clinical Research
Cranston, Rhode Island, United States
Waccamaw Pain Management
Murrells Inlet, South Carolina, United States
KRK Medical Research
Richardson, Texas, United States
Jean Brown Research
Salt Lake City, Utah, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Peniston JH, Hu X, Potts SL, Wieman MS, Turk DC. Tolerability of concomitant use of selective serotonin reuptake inhibitors or serotonin-norepinephrine reuptake inhibitors and oxymorphone extended release. Postgrad Med. 2012 Mar;124(2):114-22. doi: 10.3810/pgm.2012.03.2542.
Peniston JH, Xiang Q, Gould EM. Factors affecting acceptability of titrated oxymorphone extended release in chronic low back pain - an individual patient analysis. Curr Med Res Opin. 2010 Aug;26(8):1861-71. doi: 10.1185/03007995.2010.490457.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
EN3202-032
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.